Loading news...
Miracle Mile Advisors LLC cut its stake in shares of Agilent Technologies, Inc. (NYSE: A) by 53.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,257 shares of the medical research company's stock after selling 4,925 shares during the quarter. Miracle
Boston Trust Walden Corp lowered its position in shares of Agilent Technologies, Inc. (NYSE: A) by 17.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 229,761 shares of the medical research company's stock after selling 48,731 shares during the period. Boston
Agilent Technologies, Inc. (NYSE: A - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the sixteen analysts that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to
Agilent (A) reported earnings 30 days ago. What's next for the stock?
Bloomberg's 2026 Dividend Focus list highlights 14 ‘safer' stocks with free cash flow yields exceeding dividend yields, signaling potential buy opportunities. Top projected net gainers for 2026 include Marvell Technology (MRVL), Nike (NKE), and PT Telekom Indonesia (TLK), with analyst-estimated gains up to 37.98%. Four ‘IDEAL' stocks—Aviva, Sodexo, Danske Bank, and Western Midstream—offer dividends from $1,000 invested greater than their share price, meeting the dogcatcher ‘watch to buy' threshold.
Osaic Holdings Inc. grew its holdings in Agilent Technologies, Inc. (NYSE: A) by 35.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 68,053 shares of the medical research company's stock after purchasing an additional 17,817 shares during the period. Osaic Holdings Inc.'s
Corient Private Wealth LLC trimmed its stake in shares of Agilent Technologies, Inc. (NYSE: A) by 3.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 185,108 shares of the medical research company's stock after selling 6,313 shares
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference at 9 to 9:40 a.m. PST on Tuesday, Jan. 13, 2026. A live audio webcast and replay of the presentation will be available through Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technolog.
Balyasny Asset Management L.P. decreased its position in Agilent Technologies, Inc. (NYSE: A) by 11.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,295,310 shares of the medical research company's stock after selling 173,468 shares during the
Frontier Capital Management Co. LLC cut its position in Agilent Technologies, Inc. (NYSE: A) by 22.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 204,142 shares of the medical research company's stock after selling 58,730 shares during
Pre-Market Stock Futures: The futures are trading flat on Tuesday after we opened the week on the downside, with all major indices finishing the day lower. With the Federal Reserve meeting this week, investors are playing a wait-and-see game before bidding stocks higher to ensure there will indeed be a 25-basis-point cut. Wall Street will... Here Are Tuesday's Top Wall Street Analyst Research Calls: Agilent, Alibaba, Delta Air Lines, Intel, JD.com, Micron Technology, Reddit and More.
biote (NASDAQ: BTMD - Get Free Report) and Agilent Technologies (NYSE: A - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations. Profitability This table compares biote and Agilent Technologies' net
Edgestream Partners L.P. trimmed its position in shares of Agilent Technologies, Inc. (NYSE: A) by 51.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,436 shares of the medical research company's stock after selling 19,321 shares during the period.
Agilent Technologies, Inc. (A) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Groupe la Francaise increased its holdings in shares of Agilent Technologies, Inc. (NYSE: A) by 16.5% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,596 shares of the medical research company's stock after buying an additional 5,333 shares
The Magnificent 7 AI tech stocks have served as the rocket fuel propelling the S&P 500 on its bull run over the past few years.
Examine Agilent's (A) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc (NYSE: A) today announced the release of a new 21 CFR Part 11 compliance software for the Agilent xCELLigence Real-Time Cell Analysis (RTCA) eSight system. The software includes a compliance license and enhanced security features, allowing this multiplex live-cell analysis system to be deployed not only in drug discovery and development labs but now also in GMP-regulated manufacturing and quality control settings. Extending the plat.
A group of dividend raisers OBT, UBSI, DDS, PATK and A stand out as investors seek stability amid volatile markets, rate-cut hopes and mixed economic signals.
Agilent Technologies delivered strong Q4 2025 results, with revenue and EPS beating expectations and robust growth in Life Sciences and Diagnostics segment. Management forecasts FY26 revenue growth of 6% and normalized EPS between $5.86 and $6.00, signaling continued solid performance. Agilent now trades at a 6% premium to fair value after a 23% rally, outpacing the S&P 500 handily since my August coverage.